共 50 条
Health-state utilities and quality of life in hepatitis C patients
被引:1
|作者:
Chong, CAKY
Gulamhussein, A
Heathcote, EJ
Lilly, L
Sherman, M
Naglie, G
Krahn, M
机构:
[1] Univ Toronto, Fac Med, Toronto, ON, Canada
[2] Univ Toronto, Program Clin Epidemiol & Hlth Care Res, Toronto, ON, Canada
[3] Univ Hlth Network, Dept Med, Toronto, ON, Canada
来源:
关键词:
D O I:
10.1016/S0002-9270(02)06054-9
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
OBJECTIVE: Health-state utilities are global measurements of quality of life on a scale from 0 (death) to I (full health). Utilities are used to evaluate health outcomes and are the preferred outcome measure for policy models that determine the cost-effectiveness of treatments. Currently, utilities for hepatitis C virus (HCV)-infected patients have been estimated using expert judgments. The purpose of this study was to elicit HCV utilities directly from patients. METHODS: We assessed the utilities of 193 outpatients at various stages of chronic HCV progression by using a visual analog scale, the standard gamble technique, the Health Utilities Index Mark 3 survey, and the EuroQol Index survey. We also incorporated the nonutility-based Short Form-36v2 survey, which provides a detailed profile of health status. RESULTS: The mean standard gamble utilities were: 0.78 for patients without a recent liver biopsy and no signs of cirrhosis; 0.79 for mild to moderate chronic HCV infection; 0.80 for compensated cirrhosis; 0.60 for decompensated cirrhosis; 0.72 for hepatocellular carcinoma; 0.73 for transplant; and 0.86 for sustained virological responders to interferon +/- ribavirin treatment. The Health Utilities Index Mark 3 survey and the EuroQol Index survey utilities were lower than Canadian population norms (p < 0.001). Patient-elicited utilities were lower than previous expert estimates for mild/moderate chronic infection and sustained virological responders, but higher for decompensated cirrhosis and hepatocellular carcinoma. The Short Form-36v2 survey scores revealed several significant health impairments (p < 0.005) when compared with U.S. population norms. CONCLUSIONS: These findings 1) suggest that quality of life (QOL) differences across the HCV clinical spectrum are smaller than previously believed; 2) support other evidence suggesting that QOL is significantly diminished in HCV patients; and 3) provide utility values derived directly from HCV patients.
引用
收藏
页码:630 / 638
页数:9
相关论文